DanGer Shock-like profile predicts the outcome in ST-elevation myocardial infarction-related cardiogenic shock.

ABSTRACT:

Aims

The DanGer Shock (DGS) trial demonstrated that the routine use of a microaxial flow pump (mAFP) with standard care to treat STEMI-related cardiogenic shock (STEMI-CS) led to a lower risk of all-cause death at 180 days than standard care alone. We investigated the impact of patient eligibility for DGS in an all-comers cardiogenic shock registry of patients receiving a mAFP.

Methods and results

Prospective single-centre mAFP registry including 478 CS-patients with 225 patients having STEMI-CS. DGS-like was defined as STEMI-CS, lactate ≥2.5 mmol/L, left ventricular ejection fraction < 45%, no mechanical complications, and no comatose out-of-hospital cardiac arrest but in-hospital cardiac arrest with a maximum of 10 min to return of spontaneous circulation as a surrogate fo

SUBMITTER: Mangner N 

PROVIDER: S-EPMC12287854 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature